eprintid: 10073483
rev_number: 16
eprint_status: archive
userid: 608
dir: disk0/10/07/34/83
datestamp: 2019-05-09 09:17:34
lastmod: 2021-10-18 00:17:38
status_changed: 2019-05-09 09:17:34
type: article
metadata_visibility: show
creators_name: Smith, R
creators_name: Schöll, M
creators_name: Londos, E
creators_name: Ohlsson, T
creators_name: Hansson, O
title: <sup>18</sup>F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies
ispublished: pub
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
note: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
abstract: Mixed pathologies of α-synuclein, β-amyloid and tau are relatively common in Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB). We therefore wanted to study the retention patterns of 18F-AV-1451 in PD, PD-dementia (PDD), and DLB. To do this 44 healthy controls, 11 non-demented patients with PD, 18 patients with PDD, and six patients with DLB underwent MRI and 18F-AV-1451 PET scanning and cognitive testing. We found that parietal 18F-AV-1451 retention was increased in patients with DLB compared to controls and PD patients, while 18F-AV-1451 uptake was reduced in the substantia nigra in PDD. Increased parietal 18F-AV-1451 PET uptake was associated with impaired performance on verbal fluency tests, and the decreased uptake in the substantia nigra correlated with worse motor function. We found no effect of the monoamine oxidase B inhibitor rasagiline on 18F-AV-1451 binding. In conclusion DLB patients have increased parietal 18F-AV-1451 uptake. Increased parietal tau is associated with executive impairment in patients with synucleinopathies, while decreased uptake in the substantia nigra is associated with parkinsonism. Further, our data indicate that 18F-AV-1451 does not significantly bind to MAO-B in vivo.
date: 2018-03-16
date_type: published
official_url: https://doi.org/10.1038/s41598-018-23041-x
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 1652776
doi: 10.1038/s41598-018-23041-x
lyricists_name: Scholl, Michael
lyricists_id: MSCHO84
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: Scientific Reports
volume: 8
article_number: 4717
issn: 2045-2322
citation:        Smith, R;    Schöll, M;    Londos, E;    Ohlsson, T;    Hansson, O;      (2018)    <sup>18</sup>F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies.                   Scientific Reports , 8     , Article 4717.  10.1038/s41598-018-23041-x <https://doi.org/10.1038/s41598-018-23041-x>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10073483/1/s41598-018-23041-x.pdf